ALPMF Projected Dividend Yield
Ord/Astellas Pharma Inc ( OTCBB : ALPMF )Astellas Pharma is mainly engaged in the research and development, manufacture, and sale of pharmaceuticals globally. Co.'s main products include XTANDI, Prograf, Betanis/Myrbetriq/BETMIGA, XOSPATA, Evrenzo, PADCEV, and other. XTANDI is an androgen receptor signaling inhibitor indicated for the treatment of forms of advanced prostate cancer. Betanis/Myrbetriq/BETMIGA is for Overactive Bladder (OAB) treatment, a beta-3 adrenergic receptor agonist. XOSPATA is a FLT3 inhibitor for adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) with a FLT3 mutation-positive. PADCEV (enfortumab vedotin) is a treatment for patients with locally advanced or metastatic urothelial cancer. 25 YEAR PERFORMANCE RESULTS |
ALPMF Dividend History Detail ALPMF Dividend News ALPMF Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend Amount (JPY) |
2024 |
N/A |
N/A |
Sep 30, 2024 |
Dec 02, 2024 |
37.0000 |
2024 |
N/A |
N/A |
Mar 31, 2024 |
Jun 03, 2024 |
35.0000 |
2024 Total: |
72.0000 |
||||
2023 |
N/A |
N/A |
Sep 30, 2023 |
Dec 01, 2023 |
35.0000 |
2023 |
N/A |
N/A |
Mar 31, 2023 |
Jun 01, 2023 |
30.0000 |
2023 Total: |
65.0000 |
||||
2022 |
N/A |
N/A |
Sep 30, 2022 |
Dec 01, 2022 |
30.0000 |
2022 |
N/A |
N/A |
Mar 31, 2022 |
Jun 01, 2022 |
25.0000 |
2022 Total: |
55.0000 |
||||
2021 |
N/A |
N/A |
Sep 30, 2021 |
Dec 01, 2021 |
25.0000 |
2021 |
N/A |
N/A |
Mar 31, 2021 |
Jun 01, 2021 |
21.0000 |
2021 Total: |
46.0000 |
||||
2020 |
N/A |
N/A |
Sep 30, 2020 |
Dec 01, 2020 |
21.0000 |
2020 |
N/A |
N/A |
Mar 31, 2020 |
Jun 01, 2020 |
20.0000 |
2020 Total: |
41.0000 |
||||
2019 |
N/A |
N/A |
Sep 30, 2019 |
Dec 02, 2019 |
20.0000 |
2019 |
N/A |
N/A |
Mar 31, 2019 |
Jun 19, 2019 |
19.0000 |
2019 Total: |
39.0000 |